XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results

XBiotech (NASDAQ:XBIT - Get Free Report) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.34) EPS for the quarter, Zacks reports.

XBiotech Stock Down 0.3 %

NASDAQ:XBIT traded down $0.01 during trading hours on Friday, hitting $3.44. 67,434 shares of the company traded hands, compared to its average volume of 79,057. The firm's 50-day simple moving average is $3.38 and its 200-day simple moving average is $5.46. XBiotech has a one year low of $2.94 and a one year high of $9.96. The company has a market cap of $104.86 million, a PE ratio of -3.19 and a beta of 1.25.

Hedge Funds Weigh In On XBiotech

A hedge fund recently raised its stake in XBiotech stock. Bank of America Corp DE lifted its holdings in shares of XBiotech Inc. (NASDAQ:XBIT - Free Report) by 42.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,888 shares of the biopharmaceutical company's stock after purchasing an additional 5,887 shares during the period. Bank of America Corp DE owned about 0.07% of XBiotech worth $79,000 at the end of the most recent reporting period. Institutional investors own 55.70% of the company's stock.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.